|
1
|
Boyle P and Langman JS: ABC of colorectal
cancer: Epidemiology. BMJ. 321:805–808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar
|
|
3
|
Fearnhead NS, Britton MP and Bodmer WF:
The ABC of APC. Hum Mol Genet. 10:721–733. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
5
|
Fodde R, Smits R and Clevers H: APC,
signal transduction and genetic instability in colorectal cancer.
Nat Rev Cancer. 1:55–67. 2001. View
Article : Google Scholar
|
|
6
|
Vermeulen L, De Sousa E Melo F, van der
Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M,
Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat Cell Biol.
12:468–476. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ilmer M, Boiles AR, Regel I, Yokoi K,
Michalski CW, Wistuba II, Rodriguez J, Alt E and Vykoukal J: RSPO2
enhances canonical Wnt signaling to confer stemness-associated
traits to susceptible pancreatic cancer cells. Cancer Res.
75:1883–1896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prud’homme GJ: Cancer stem cells and novel
targets for antitumor strategies. Curr Pharm Des. 18:2838–2849.
2012. View Article : Google Scholar
|
|
9
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagler C, Zänker KS and Dittmar T: Cell
fusion, drug resistance and recurrence CSCs. Adv Exp Med Biol.
714:173–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quartara L and Maggi CA: The tachykinin
NK1 receptor. Part II: Distribution and pathophysiological roles.
Neuropeptides. 32:1–49. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hökfelt T, Pernow B and Wahren J:
Substance P: A pioneer amongst neuropeptides. J Intern Med.
249:27–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varty GB, Cohen-Williams ME and Hunter JC:
The antidepressant-like effects of neurokinin NK1 receptor
antagonists in a gerbil tail suspension test. Behav Pharmacol.
14:87–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosso M, Muñoz M and Berger M: The role of
neurokinin-1 receptor in the microenvironment of inflammation and
cancer. Sci World J. 2012:3814342012.
|
|
15
|
Muñoz M and Coveñas R: Neurokinin-1
receptor: A new promising target in the treatment of cancer. Discov
Med. 10:305–313. 2010.PubMed/NCBI
|
|
16
|
Muñoz M, Rosso M and Coveñas R: A new
frontier in the treatment of cancer: NK-1 receptor antagonists.
Curr Med Chem. 17:504–516. 2010. View Article : Google Scholar
|
|
17
|
Kramer MS1, Winokur A, Kelsey J, Preskorn
SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack
D, et al: Demonstration of the efficacy and safety of a novel
substance P (NK1) receptor antagonist in major depression.
Neuropsychopharmacology. 29:385–392. 2004. View Article : Google Scholar
|
|
18
|
Kramer MS, Cutler N, Feighner J,
Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D,
Wyatt-Knowles E, et al: Distinct mechanism for antidepressant
activity by blockade of central substance P receptors. Science.
281:1640–1645. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berger M, Neth O, Ilmer M, Garnier A,
Salinas-Martín MV, de Agustín Asencio JC, von Schweinitz D, Kappler
R and Muñoz M: Hepatoblastoma cells express truncated neurokinin-1
receptor and can be growth inhibited by aprepitant in vitro and in
vivo. J Hepatol. 60:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muñoz M, González-Ortega A, Salinas-Martín
MV, Carranza A, Garcia-Recio S, Almendro V and Coveñas R: The
neurokinin-1 receptor antagonist aprepitant is a promising
candidate for the treatment of breast cancer. Int J Oncol.
45:1658–1672. 2014.PubMed/NCBI
|
|
21
|
Muñoz M and Rosso M: The NK-1 receptor
antagonist aprepitant as a broad spectrum antitumor drug. Invest
New Drugs. 28:187–193. 2010. View Article : Google Scholar
|
|
22
|
Bresalier RS, Niv Y, Byrd JC, Duh QY,
Toribara NW, Rockwell RW, Dahiya R and Kim YS: Mucin production by
human colonic carcinoma cells correlates with their metastatic
potential in animal models of colon cancer metastasis. J Clin
Invest. 87:1037–1045. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hennessy BT, Lu Y, Gonzalez-Angulo AM,
Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K,
Meric-Bernstam F, et al: A technical assessment of the utility of
reverse phase protein arrays for the study of the functional
proteome in non-microdissected human breast cancers. Clin
Proteomics. 6:129–151. 2010. View Article : Google Scholar
|
|
24
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Zhang W, Evans PM, Chen X, He X
and Liu C: Adenomatous polyposis coli (APC) differentially
regulates beta-catenin phosphorylation and ubiquitination in colon
cancer cells. J Biol Chem. 281:17751–17757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiza C, Nascimento EB and Ouwens DM: Role
of PRAS40 in Akt and mTOR signaling in health and disease. Am J
Physiol Endocrinol Metab. 302:E1453–E1460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bossy-Wetzel E, Bakiri L and Yaniv M:
Induction of apoptosis by the transcription factor c-Jun. EMBO J.
16:1695–1709. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leppä S and Bohmann D: Diverse functions
of JNK signaling and c-Jun in stress response and apoptosis.
Oncogene. 18:6158–6162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lazebnik YA, Kaufmann SH, Desnoyers S,
Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase
by a proteinase with properties like ICE. Nature. 371:346–347.
1994. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gespach C: Increasing potential of HER3
signaling in colon cancer progression and therapy. Clin Cancer Res.
18:917–919. 2012. View Article : Google Scholar
|
|
31
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orsulic S, Huber O, Aberle H, Arnold S and
Kemler R: E-cadherin binding prevents beta-catenin nuclear
localization and beta-catenin/LEF-1-mediated transactivation. J
Cell Sci. 112:1237–1245. 1999.PubMed/NCBI
|
|
33
|
Lonardo E, Hermann PC, Mueller MT, Huber
S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S,
Rodriguez-Arabaolaza I, Ramirez JC, et al: Nodal/Activin signaling
drives self-renewal and tumorigenicity of pancreatic cancer stem
cells and provides a target for combined drug therapy. Cell Stem
Cell. 9:433–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fuerer C and Nusse R: Lentiviral vectors
to probe and manipulate the Wnt signaling pathway. PLoS One.
5:e93702010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lepourcelet M, Chen YN, France DS, Wang H,
Crews P, Petersen F, Bruseo C, Wood AW and Shivdasani RA:
Small-molecule antagonists of the oncogenic Tcf/beta-catenin
protein complex. Cancer Cell. 5:91–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Klaus A and Birchmeier W: Wnt signalling
and its impact on development and cancer. Nat Rev Cancer.
8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gong A and Huang S: FoxM1 and
Wnt/β-catenin signaling in glioma stem cells. Cancer Res.
72:5658–5662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshida Y, Wang IC, Yoder HM, Davidson NO
and Costa RH: The forkhead box M1 transcription factor contributes
to the development and growth of mouse colorectal cancer.
Gastroenterology. 132:1420–1431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lickert H, Bauer A, Kemler R and Stappert
J: Casein kinase II phosphorylation of E-cadherin increases
E-cadherin/beta-catenin interaction and strengthens cell-cell
adhesion. J Biol Chem. 275:5090–5095. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gonsalves FC, Klein K, Carson BB, Katz S,
Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM and DasGupta R:
An RNAi-based chemical genetic screen identifies three
small-molecule inhibitors of the Wnt/wingless signaling pathway.
Proc Natl Acad Sci USA. 108:5954–5963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tian W, Han X, Yan M, Xu Y, Duggineni S,
Lin N, Luo G, Li YM, Han X, Huang Z, et al: Structure-based
discovery of a novel inhibitor targeting the β-catenin/Tcf4
interaction. Biochemistry. 51:724–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mayordomo C, García-Recio S, Ametller E,
Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón
P and Almendro V: Targeting of substance P induces cancer cell
death and decreases the steady state of EGFR and Her2. J Cell
Physiol. 227:1358–1366. 2012. View Article : Google Scholar
|
|
44
|
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang
Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, et al: TSC2
integrates Wnt and energy signals via a coordinated phosphorylation
by AMPK and GSK3 to regulate cell growth. Cell. 126:955–968. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Breuleux M, Klopfenstein M, Stephan C,
Doughty CA, Barys L, Maira SM, Kwiatkowski D and Lane HA: Increased
AKT S473 phosphorylation after mTORC1 inhibition is rictor
dependent and does not predict tumor cell response to PI3K/mTOR
inhibition. Mol Cancer Ther. 8:742–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
